Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2024-05-08 DOI:10.1111/irv.13294

Clara Mazagatos, Jacobo Mendioroz, Mercedes Belén Rumayor, Virtudes Gallardo García, Virginia Álvarez Río, Ana Delia Cebollada Gracia, Noa Batalla Rebollo, María Isabel Barranco Boada, Olaia Pérez-Martínez, Ana Sofía Lameiras Azevedo, Nieves López González-Coviella, Daniel Castrillejo, Ana Fernández Ibáñez, Jaume Giménez Duran, Cristina Ramírez Córcoles, Violeta Ramos Marín, Amparo Larrauri, Susana Monge, The SARI Sentinel Surveillance RSV Study Group

{"title":"Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain","authors":"Clara Mazagatos, Jacobo Mendioroz, Mercedes Belén Rumayor, Virtudes Gallardo García, Virginia Álvarez Río, Ana Delia Cebollada Gracia, Noa Batalla Rebollo, María Isabel Barranco Boada, Olaia Pérez-Martínez, Ana Sofía Lameiras Azevedo, Nieves López González-Coviella, Daniel Castrillejo, Ana Fernández Ibáñez, Jaume Giménez Duran, Cristina Ramírez Córcoles, Violeta Ramos Marín, Amparo Larrauri, Susana Monge, The SARI Sentinel Surveillance RSV Study Group","doi":"10.1111/irv.13294","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13294","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13294","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.

Methods

Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.

Results

We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2023年第40周至2024年第8周，西班牙，Nirsevimab对需住院治疗的1岁以下儿童呼吸道合胞病毒感染发生率的影响估计。

背景利用西班牙严重急性呼吸道感染哨点监测系统的数据来估算对 2023 年 4 月 1 日以后出生的儿童使用尼舍单抗的影响：方法：估算结果：我们估计 RSV 住院人数比预期减少了 9364-9875 例，相当于减少了 74%-75% 的住院人数。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.